Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco
Nearly all those treated in a recent trial were cured.
People without hep C received kidney, liver or heart transplants from HCV-positive donors and then were treated for the virus.
The study population included those with all hepatitis C genotypes—except genotype 3.
A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.
Hepatitis C patient is cured with Mavyret; she continues to share her treatment experience in part 2 of this interview with Connie Welch.
Hepatitis C patient is cured with Mavyret, one of the newest highly effective hepatitis C treatments out on the market.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.
This is according to a recent mathematical modeling study.
Among those without cirrhosis, treating for an additional four weeks is unnecessary.
Nearly all those who have recently completed treatment in an Italian cohort are apparently poised for a cure.
Those for whom Mavyret did not work the first time had a high cure rate with this intensified retreatment regimen.
A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC
The recently approved combination tablet includes the medications glecaprevir and pibrentasvir.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.